E pluribus unum: Combining Molecular Strategies to Defeat Head and Neck Cancer

Affiliations

Comment

John Barrett. Mol Ther. 2017.

. 2017 Nov 1;25(11):2434-2435.

doi: 10.1016/j.ymthe.2017.10.006. Epub 2017 Oct 19.

¹ Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: barrettjj@mail.nih.gov.

No abstract available

Comment on

Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.
Rosewell Shaw A, Porter CE, Watanabe N, Tanoue K, Sikora A, Gottschalk S, Brenner MK, Suzuki M. Rosewell Shaw A, et al. Mol Ther. 2017 Nov 1;25(11):2440-2451. doi: 10.1016/j.ymthe.2017.09.010. Epub 2017 Sep 14. Mol Ther. 2017. PMID: 28974431 Free PMC article.

1. Lo Nigro C., Denaro N., Merlotti A., Merlano M. Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Manag. Res. 2017;9:363–371. - PMC - PubMed
1. Shaw A.R., Porter C.E., Watanabe N., Tanoue K., Sikora A., Gottschalk S., Brenner M.K., Suzuki M. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments chimeric antigen receptor T-cell against metastatic head and neck cancer. Mol. Ther. 2017;25:2440–2451. this issue. - PMC - PubMed
1. Howells A., Marelli G., Lemoine N.R., Wang Y. Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer. Front. Oncol. 2017;7:195. - PMC - PubMed
1. Kwok G., Yau T.C., Chiu J.W., Tse E., Kwong Y.L. Pembrolizumab (Keytruda) Hum. Vaccin. Immunother. 2016;12:2777–2789. - PMC - PubMed
1. Pollock N.I., Grandis J.R. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin. Cancer Res. 2015;21:526–533. - PMC - PubMed